Hutchison China MediTech (Chi-Med) Webcast Presentation Now Available For On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference

Company invites individual and institutional investors, as well as advisors, to log-on to view the presentation

HONG KONG, June 13, 2016 /PRNewswire/ -- Hutchison China MediTech (LONDON STOCK EXCHANGE: HCM, NASDAQ: HCM) based in China, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Today announced that their June 10 presentation from Chief Executive Officer, Christian Hogg, is now available for on-demand viewing in the dbVIC Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference.

LINK:  www.adr.db.com/dbvic

Hutchison China MediTech presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the virtual trade booth in the Exhibits section of the event.

Recent Company Highlights

About Hutchison China MediTech

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products. Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China. Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: http://www.chi-med.com

Read more: http://www.nasdaq.com/article/hutchison-china-meditech-limited-hcm-interview-withchristian-hoggexecutive-director-andceo-cm603190#ixzz49BwmhNqp

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/hutchison-china-meditech-webcast-presentation-now-available-for-on-demand-viewing-dbvic---deutsche-bank-adr-virtual-investor-conference-300279939.html

SOURCE Hutchison China MediTech

Back to news